Supplementary Materials
Supplementary Material for:
Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools
Kasper Lamberth,* Stine Louise Reedtz-Runge, Jonathan Simon, Ksenia Klementyeva, Gouri Shankar Pandey, Søren Berg Padkjær, Véronique Pascal, Ileana R. León, Charlotte Nini Gudme, Søren Buus, Zuben E. Sauna*
*Corresponding author. Email: zuben.sauna{at}fda.hhs.gov (Z.E.S.); kplm{at}novonordisk.com (K.L.)
Published 11 January 2017, Sci. Transl. Med. 9, eaag1286 (2017)
DOI: 10.1126/scitranslmed.aag1286
This PDF file includes:
- Materials and Methods
- Table S1. Synthetic peptides used in the ELISpot assays shown in Fig. 3.
- Table S2. Synthetic peptides used in the ELISpot and proliferation assays depicted in Fig. 4.
- Table S3. List of MHC-II DRB1 variants depicted in Fig. 5D.
- Fig. S1. Heat maps similar to the one depicted in Fig. 1D plotted on different scales for peptide–MHC-II affinity.
- Reference (29)